Journal article
Multiomics medicine in oncology: Assessing effectiveness, cost-effectiveness and future research priorities for the molecularly unique individual
B Doble, A Harris, DM Thomas, S Fox, P Lorgelly
Pharmacogenomics | FUTURE MEDICINE LTD | Published : 2013
DOI: 10.2217/pgs.13.142
Abstract
The development of genomic technologies has ushered in the era of pharmacogenomics. However, discoveries and clinical use of targeted therapies are still in their infancy. A focus on monogenic pharmacogenetic traits may contribute to this lack of progress. Variation in drug response is likely a complex paradigm involving not only genomic factors but proteomic, metabolomic and epigenomic influences. The incorporation of these omics elements into pharmaceutical development and clinical decision-making will ultimately require the use of methods to determine clinical and economic value. Current methodologies and guidelines for determining clinical effectiveness and cost-effectiveness may have li..
View full abstractGrants
Funding Acknowledgements
B Doble is supported by research scholarships from Monash University. D Thomas, S Fox and P Lorgelly are recipients of a Victorian Government Translational Research Grant through the Victorian Cancer Agency. The funding sources had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review and approval of the manuscript; or decision to submit the manuscript for publication. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.